Atrial Septal Defect Market

The global atrial septal defect market size is projected to expand a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the wide prevalence of heart diseases, rising disposable income of the population of developing regions, and growing awareness about advanced diagnostics procedures and treatment.

Atrial septal defect (ASD) is an inborn heart defect, in which the proper blood flows is disturbed due to the formation of a hole in the wall between the atria, the upper heart chamber. The atria are portion of the hearts upper chamber and are separated by interatrial septum. When interatrial septum is absent or found defective, the blood from left side directly flows and get mixed with the right side of the oxygen deficient blood of the heart. ASD is very common congenital cardiac diseases and, is generally occurred more to women than men. When a baby is born with the opening of the interatrial septum, it is likely to create a hole in the heart, which is called as ASD.

Long-term ASD causes severe lung and heart damage and the detection of ASD through diagnostics is normally conducted when the baby attains the adulthood. If the defect is small, then it usually does not show any symptoms but it leads to lower the oxygen level in the arterial blood, which is supplied to different organs such as tissues and brain. At the time of fetus development, the interatrial septum is developed for separation of left and right atria and a hole is present in the interatrial septum that is known as foremen ovale or foremen septum. During fetal development, the blood movement from right atrium to left atrium is allowed by foremen ovale. This opening helps fetus to bypass the fetal lungs which are nonfunctional to get oxygen from placenta.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing prevalence of heart disorders and diseases among a large number of population especially in Asia Pacific is projected to drive the market growth during the forecast period.
•  Several governments’ initiatives and policies encouraging drug development and advanced diagnostics devices to offer effective treatment of ASD are likely to propel the market growth.
• Growing awareness of the defect and rising demand for the development of advanced diagnostic technology are key factors responsible to boost the market growth.
• High maintenance cost of installing treatment devices and lack of technical skills are projected to hamper the market growth
• Technological advancement and R&D activities to enhance existing treatment devices for ASD are expected to create opportunities for the market growth.

Scope of Atrial Septal Defect Market Report

The report on the global atrial septal defect market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Atrial Septal Defect Market Segment Insights

Electrocardiogram segment is projected to hold a key market share

On the basis of diagnosis, the global atrial septal defect market is segmented into chest X-ray, electrocardiogram, cardiac catherization, transesophageal echocardiography (TEE), and pulse oximetrey. The electrocardiogram segment is expected to hold a key share of the market during the forecast period owing to advanced technologies and increase in accessibility to advanced treatments. Electrocardiogram (ECG) deals with recording electrical signal from heart of an individual and detecting heart problems. Rising occurrence of heart diseases across the globe is major factor responsible for driving the segment growth.

For diagnosis of ASD, chest X-ray test is widely used in order to detect the condition of lungs and heart. Transesophageal echocardiography (TEE) test provides ultrasound image, which gives clear image of the atria. Pulse oximetrey test is used to identify whether oxygenated blood is mixing with deoxygenated blood. Medications such as anti-platelet agents, beta blockers, and anticoagulants are also used to reduce signs and symptoms of ASD. In some serious and major conditions, surgery such as such as open-heart surgery and cardiac cauterization are used for repairing ASD. Meanwhile, the cardiac catherization test is adopted for diagnosis of any inborn heart defects examining the oxygen present in the blood. In this test, catheter is inserted into heat or though vein. The cardiac catherization segment is projected to grow owing to growing burden on neurology disorder, rising demand for antimicrobial catheters, and urology disorders.
 

Asia Pacific is expected to dominate the market

On the basis of regions, the global atrial septal defect market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to expand at an impressive CAGR during the forecast period. North America accounted for a major market share in 2020, which was followed by Europe. In these regions, there are some major factors such as high occurrence of genetic disorders and increasing awareness about arterial septal defects among people, which are responsible for the regional market growth. Use of advanced technology in treatment of congenital heart diseases is likely to fuel the regional market growth.

On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to the presence of a large population base in the region. Moreover, presence of emerging economies focusing on the development of the healthcare infrastructure is expected to propel the regional market growth during the forecast period.

Segments

The global atrial septal defect market has been segmented on the basis of

Diagnosis

• Chest X-ray
• Electrocardiogram (ECG)
• Cardiac Catherization
• Transesophageal Echocardiography (TEE)
• Pulse Oximetrey

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Asklepion Pharmaceuticals LLC
• Actelion Ltd
• Novo Nordisk A/S
• Abbott Laboratories
• INO Therapeutics
• St. Jude Medical
• Occlutech
• W. L. Gore & Associates
• Boston Scientific Corp
• SentreHEART
• Coherex Medical
• Starway
• LifeTech
• Lepu Medical Technology
• MicroPort
• Beijing Balance Medical Technology
• Mallow medical
• Visee Medical Devices
• Ya Tai Science & Technology

Competitive Landscape

Key players competing in the global atrial septal defect market include Asklepion Pharmaceuticals, LLC; Actelion Ltd; Novo Nordisk A/S; Abbott Laboratories; INO Therapeutics; St. Jude Medical; Occlutech; W. L. Gore & Associates; Boston Scientific Corp.; SentreHEART; Coherex Medical; Starway; LifeTech; Lepu Medical Technology; MicroPort; Beijing Balance Medical Technology; Mallow medical; Visee Medical Devices; and Ya Tai Science & Technology.

Major players are constantly focusing on several market strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase or enhance their market shares.